Strata Critical Medical Inc（SRTA）财务数据SRTAStrata Critical Medical Inc

Strata Critical Medical, Inc. (SRTA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Logistics, accounting for 66.5% of total sales, equivalent to $48.24M. Another important revenue stream is Clinical. Understanding this composition is critical for investors evaluating how SRTA navigates market cycles within the Courier, Postal, Air Freight & Land-based Logistics industry.

Evaluating the bottom line, Strata Critical Medical, Inc. maintains a gross margin of 11.84%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -7.46%, while the net margin is -14.50%. These profitability ratios, combined with a Return on Equity (ROE) of -9.22%, provide a clear picture of how effectively SRTA converts its operational activities into shareholder value.

In the context of the broader market, SRTA competes directly with industry leaders such as FLGT and DNA. With a market capitalization of $545.84M, it holds a leading position in the sector. When comparing efficiency, SRTA's gross margin of 11.84% stands against FLGT's 27.02% and DNA's 91.47%. Such benchmarking helps identify whether Strata Critical Medical, Inc. is trading at a premium or discount relative to its financial performance.

Strata Critical Medical has shown a strong upward trend in revenue, with Q2 2026 revenue at $72.5 million, and a gross margin of 11.84%. Despite some losses in net income, the company is expected to improve its financial performance in the upcoming quarters.